Moreover, use of an SGLT-2 inhibitor was associated with a lower incidence of heart failure in patients without CKD: RR 0.78 (95% CI 0.70–0.86; P < 0.001) (Fig. 2 and Table 3). Here, SLC5A2 is linked to heart failure.